Department of Cardiovascular Sciences, Leicester Royal Infirmary, Leicester, UK.
Trials. 2010 Feb 19;11:16. doi: 10.1186/1745-6215-11-16.
Earlier diagnosis followed by multi-factorial cardiovascular risk intervention may improve outcomes in type 2 diabetes mellitus (T2DM). Latent phase identification through screening requires structured, appropriately targeted population-based approaches. Providers responsible for implementing screening policy await evidence of clinical and cost effectiveness from randomised intervention trials in screen-detected T2DM cases. UK South Asians are at particularly high risk of abnormal glucose tolerance and T2DM. To be effective national screening programmes must achieve good coverage across the population by identifying barriers to the detection of disease and adapting to the delivery of earlier care. Here we describe the rationale and methods of a systematic community screening programme and randomised controlled trial of cardiovascular risk management within a UK multiethnic setting (ADDITION-Leicester).
A single-blind cluster randomised, parallel group trial among people with screen-detected T2DM comparing a protocol driven intensive multi-factorial treatment with conventional care.
ADDITION-Leicester consists of community-based screening and intervention phases within 20 general practices coordinated from a single academic research centre. Screening adopts a universal diagnostic approach via repeated 75g-oral glucose tolerance tests within an eligible non-diabetic population of 66,320 individuals aged 40-75 years (25-75 years South Asian). Volunteers also provide detailed medical and family histories; complete health questionnaires, undergo anthropometric measures, lipid profiling and a proteinuria assessment. Primary outcome is reduction in modelled Coronary Heart Disease (UKPDS CHD) risk at five years. Seven thousand (30% of South Asian ethnic origin) volunteers over three years will be recruited to identify a screen-detected T2DM cohort (n = 285) powered to detected a 6% relative difference (80% power, alpha 0.05) between treatment groups at one year. Randomisation will occur at practice-level with newly diagnosed T2DM cases receiving either conventional (according to current national guidelines) or intensive (algorithmic target-driven multi-factorial cardiovascular risk intervention) treatments.
ADDITION-Leicester is the largest multiethnic (targeting >30% South Asian recruitment) community T2DM and vascular risk screening programme in the UK. By assessing feasibility and efficacy of T2DM screening, it will inform national disease prevention policy and contribute significantly to our understanding of the health care needs of UK South Asians.
Clinicaltrial.gov (NCT00318032).
早期诊断并采取多因素心血管风险干预措施可能会改善 2 型糖尿病(T2DM)患者的结局。通过筛查确定潜伏期需要采用结构化、有针对性的基于人群的方法。负责实施筛查政策的提供者正在等待随机干预试验在筛查出的 T2DM 病例中提供临床和成本效益的证据。英国南亚裔人群的葡萄糖耐量异常和 T2DM 风险特别高。有效的国家筛查计划必须通过识别疾病检测障碍并适应早期护理的提供,在整个人群中实现良好的覆盖率。在这里,我们描述了在英国多种族环境中进行系统社区筛查计划和心血管风险管理随机对照试验的基本原理和方法(ADDITION-Leicester)。
一项在筛查出的 T2DM 患者中进行的单盲、聚类随机、平行组试验,比较了一种基于方案的强化多因素治疗与常规治疗。
ADDITION-Leicester 由 20 个基层医疗实践中的社区筛查和干预阶段组成,由一个单一的学术研究中心协调。筛查采用重复的 75g 口服葡萄糖耐量试验,对 66320 名年龄在 40-75 岁(25-75 岁南亚裔)的非糖尿病合格人群进行普遍诊断。志愿者还提供详细的医疗和家族史;完成健康问卷,进行人体测量、血脂分析和蛋白尿评估。主要结局是五年时模型化的冠心病(英国前瞻性糖尿病研究冠心病)风险降低。在三年内,将招募 7000 名(30%为南亚裔)志愿者,以确定一个筛查出的 T2DM 队列(n=285),该队列有能力在一年内检测到治疗组之间 6%的相对差异(80%的效力,α=0.05)。将在实践层面进行随机分组,新诊断的 T2DM 病例将接受常规(根据当前国家指南)或强化(基于算法的目标驱动的多因素心血管风险干预)治疗。
ADDITION-Leicester 是英国最大的多种族(目标是 30%以上的南亚裔招募)社区 T2DM 和血管风险筛查计划。通过评估 T2DM 筛查的可行性和疗效,它将为国家疾病预防政策提供信息,并为我们了解英国南亚裔的医疗保健需求做出重大贡献。
Clinicaltrial.gov(NCT00318032)。